A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Positive Solid Tumors
Interventions: DRUG: SBT6050|DRUG: pembrolizumab|DRUG: Cemiplimab
Sponsor: Silverback Therapeutics